Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: January 31, 2010
Business Overview: The Company operates through two primary segments: CooperVision (CVI), which develops and markets contact lenses, and CooperSurgical (CSI), which manufactures medical devices and surgical instruments for women's healthcare.
Key Financial Metrics
| Metric (in thousands) | Q1 2010 | Q1 2009 |
|---|---|---|
| Net Sales | $260,258 | $251,142 |
| Gross Profit | $149,763 | $142,135 |
| Gross Margin | 58% | 57% |
| Operating Income | $36,979 | $32,780 |
| Net Income | $20,423 | $23,873 |
| Diluted EPS | $0.44 | $0.53 |
| Operating Cash Flow | $56,142 | $24,904 |
| Total Debt | $743,318 | $781,474 |
| Cash and Equivalents | $1,822 | $1,885 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 4% year-over-year, driven by an 11% increase in CooperSurgical sales and a 2% increase in CooperVision sales.
- Profitability: Operating income rose 13% to $37.0 million, aided by a significant reduction in restructuring costs ($0.4 million in Q1 2010 vs. $3.0 million in Q1 2009) and improved gross margins.
- Net Income Decline: Despite higher operating income, net income decreased 14% to $20.4 million. This was primarily due to a $10.5 million swing in "Other (expense) income, net," which turned from an $8.1 million gain in 2009 to a $2.3 million loss in 2010, largely driven by foreign exchange losses.
- Cash Flow: Operating cash flow more than doubled to $56.1 million, attributed to inventory reductions and timing of payments.
- Debt Reduction: Total debt decreased by approximately $38 million due to net repayments of long-term debt.
Guidance, Outlook, and Risks
- Outlook: Management remains optimistic about long-term prospects in contact lens and women's healthcare markets but cites global economic uncertainty and credit market instability as risks to fiscal 2010 performance.
- Restructuring: The Company is executing a manufacturing restructuring plan for CooperVision (relocating from Norfolk, VA, and Adelaide, Australia). Total estimated costs are $24 million, with completion expected by Q1 2011.
- Product Strategy: CooperVision is focusing on market penetration in Europe and Asia with silicone hydrogel products (Biofinity and Avaira). CooperSurgical continues to pursue acquisitions to expand its product lines.
- Legal Contingencies: The Company is defending a putative securities class action lawsuit regarding the 2005 Ocular Sciences merger and related disclosures. Summary judgment motions were denied in March 2010. The Company expects to exhaust insurance coverage for defense costs.
- Accounting Adjustments: A $6.0 million out-of-period adjustment was recorded in Q1 2010 to increase accruals for rebates under-accrued in fiscal 2009, reducing net income for the quarter.
Investor Verification Checklist
- Foreign Exchange Impact: Verify the sensitivity of future earnings to currency fluctuations, given the $2.3 million foreign exchange loss in Q1 2010.
- Restructuring Costs: Monitor the execution of the CooperVision manufacturing relocation and the realization of the projected $24 million in total costs.
- Legal Exposure: Track the status of the securities class action litigation and potential settlement costs or trial expenses.
- Rebate Accruals: Assess the impact of the $10.1 million rebate adjustment on future revenue recognition and margin stability.
- Liquidity Position: Review the Company's ability to fund operations and acquisitions given the low cash balance ($1.8 million) relative to total debt ($743 million), despite strong operating cash flow.